mskcc_motzer_score: MSKCC/Motzer Score for Metastatic Renal Cell Carcinoma

In cliot: Clinical Indices and Outcomes Tools

MSKCC/Motzer Score for Metastatic Renal Cell Carcinoma

Description

Calculates the MSKCC (Motzer) Score for predicting survival in patients with metastatic Renal Cell Carcinoma (RCC) treated with systemic therapy (historically cytokines, now relevant for tyrosine kinase inhibitors and immunotherapy benchmarking). The score stratifies patients into Favorable, Intermediate, or Poor risk groups based on 5 clinical risk factors.

Usage

mskcc_motzer_score(time_to_systemic_tx_lt_1yr, karnofsky_performance_status_lt_80,
                   serum_calcium_gt_10_mg_dl, hemoglobin_lt_lln, ldh_gt_1_5_uln)

Arguments

time_to_systemic_tx_lt_1yr	Numeric (0 or 1). Time from initial diagnosis to start of systemic therapy < 1 year. (1 = Yes).
karnofsky_performance_status_lt_80	Numeric (0 or 1). Karnofsky Performance Status < 80%. (1 = Yes).
serum_calcium_gt_10_mg_dl	Numeric (0 or 1). Serum Calcium > 10 mg/dL (>2.5 mmol/L). (1 = Yes).
hemoglobin_lt_lln	Numeric (0 or 1). Hemoglobin less than the lower limit of normal. (1 = Yes).
ldh_gt_1_5_uln	Numeric (0 or 1). Lactate Dehydrogenase > 1.5 times the Upper Limit of Normal. (1 = Yes).

Value

A list containing:

MSKCC_Motzer_Score	The calculated risk score (0-5).
Risk_Group	Classification (Favorable: 0, Intermediate: 1-2, Poor: >=3).
Median_Overall_Survival	Estimated median overall survival based on the original validation cohort.

References

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal-cell carcinoma. J Clin Oncol. 2002;20(1):289-296. doi:10.1200/JCO.2002.20.1.289

Examples

# Example 1: Poor Risk
# <1yr to tx (1), Low KPS (1), High LDH (1)
# Score = 3
mskcc_motzer_score(1, 1, 0, 0, 1)

# Example 2: Favorable Risk
# No risk factors present
# Score = 0
mskcc_motzer_score(0, 0, 0, 0, 0)

cliot documentation built on Dec. 1, 2025, 1:06 a.m.